Innate immune signaling in the myelodysplastic syndromes

Hematology/Oncology Clinics of North America

Volumn 24, Issue 2, 2010, Pages 343-359

  Starczynowski, Daniel T ^a,b,c   Karsan, Aly ^a,b,c,d  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Acute myeloid leukemia; Innate immunity; MicroRNAs; Myelodysplastic syndromes; NF B; Toll like receptor

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; CASPASE 3; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; CD135 ANTIGEN; CD40 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MYELOID DIFFERENTIATION FACTOR 88; MYOD PROTEIN; NUCLEOPHOSMIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ACUTE GRANULOCYTIC LEUKEMIA; CELL DIFFERENTIATION; CHROMOSOME TRANSLOCATION; GENE CONTROL; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; INFLAMMATION; INNATE IMMUNITY; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; STEM CELL;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; GENE EXPRESSION REGULATION; GENES, MHC CLASS II; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LEUKEMIA, MYELOID, ACUTE; MICE; MICRORNAS; MYELODYSPLASTIC SYNDROMES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, TUMOR NECROSIS FACTOR; TOLL-LIKE RECEPTORS;

EID: 77950542157     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.02.008     Document Type: Review

References (93)

1. Kimbrell D.A., Beutler B. The evolution and genetics of innate immunity. Nat Rev Genet 2001, 2(4):256-267.
2. McGettrick A.F., O'Neill L.A. Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. Br J Haematol 2007, 139(2):185-193.
3. Bradley J.R., Pober J.S. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001, 20(44):6482-6491.
4. Arend W.P., Palmer G., Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008, 223:20-38.
5. Dauphinee S.M., Karsan A. Lipopolysaccharide signaling in endothelial cells. Lab Invest 2006, 86(1):9-22.
6. Imler J.L., Hoffmann J.A. Toll receptors in innate immunity. Trends Cell Biol 2001, 11(7):304-311.
7. Wu H., Arron J.R. TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. Bioessays 2003, 25(11):1096-1105.
8. Gao J.J., Diesl V., Wittmann T., et al. Bacterial LPS and CpG DNA differentially induce gene expression profiles in mouse macrophages. J Endotoxin Res 2003, 9(4):237-243.
9. Malcolm K.C., Arndt P.G., Manos E.J., et al. Microarray analysis of lipopolysaccharide-treated human neutrophils. Am J Physiol Lung Cell Mol Physiol 2003, 284(4):L663-L670.
10. Hertzog P.J., O'Neill L.A., Hamilton J.A. The interferon in TLR signaling: more than just antiviral. Trends Immunol 2003, 24(10):534-539.
11. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
12. Taganov K.D., Boldin M.P., Chang K.J., et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006, 103(33):12481-12486.
13. O'Connell R.M., Rao D.S., Chaudhuri A.A., et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008, 205(3):585-594.
14. Chen X.M., Splinter P.L., O'Hara S.P., et al. A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J Biol Chem 2007, 282(39):28929-28938.
15. Liu G., Friggeri A., Yang Y., et al. miR-147, a microRNA that is induced upon toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Proc Natl Acad Sci U S A 2009, 106(37):15819-15824.
16. Androulidaki A., Iliopoulos D., Arranz A., et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009, 31(2):220-231.
17. Labbaye C., Spinello I., Quaranta M.T., et al. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol 2008, 10(7):788-801.
18. Starczynowski D.T., Kuchenbauer F., Argiropoulos B., et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010, 16:49-58.
19. Chen C.Z., Li L., Lodish H.F., et al. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303(5654):83-86.
20. Ueda Y., Kondo M., Kelsoe G. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med 2005, 201(11):1771-1780.
21. Nagai Y., Garrett K.P., Ohta S., et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006, 24(6):801-812.
22. Tang M., Wei X., Guo Y., et al. TAK1 is required for the survival of hematopoietic cells and hepatocytes in mice. J Exp Med 2008, 205(7):1611-1619.
23. Passegue E., Jamieson C.H., Ailles L.E., et al. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?. Proc Natl Acad Sci U S A 2003, 100(Suppl 1):11842-11849.
24. Vardiman J.W. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact 2009, [Epub ahead of print].
25. Alvarez S., Cigudosa J.C. Gains, losses and complex karyotypes in myeloid disorders: a light at the end of the tunnel. Hematol Oncol 2005, 23(1):18-25.
26. Heerema-McKenney A., Arber D.A. Acute myeloid leukemia. Hematol Oncol Clin North Am 2009, 23(4):633-654.
27. Heuser M., Argiropoulos B., Kuchenbauer F., et al. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood 2007, 110(5):1639-1647.
28. Heuser M., Sly L.M., Argiropoulos B., et al. Modelling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. Blood 2009, 114:3983-3993.
29. Heuser M., Beutel G., Krauter J., et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 2006, 108(12):3898-3905.
30. Kelly L.M., Liu Q., Kutok J.L., et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002, 99(1):310-318.
31. Turzanski J., Grundy M., Russell N.H., et al. Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways. Leukemia 2004, 18(10):1662-1670.
32. Zapata J.M., Krajewska M., Krajewski S., et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol 2000, 165(9):5084-5096.
33. Guzman M.L., Neering S.J., Upchurch D., et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98(8):2301-2307.
34. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3(9):745-756.
35. Horie R., Gattei V., Ito K., et al. Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms. Am J Pathol 1999, 155(6):2029-2041.
36. Soni V., Cahir-McFarland E., Kieff E. LMP1 TRAFficking activates growth and survival pathways. Adv Exp Med Biol 2007, 597:173-187.
37. Aldinucci D., Poletto D., Nanni P., et al. CD40L induces proliferation, self-renewal, rescue from apoptosis, and production of cytokines by CD40-expressing AML blasts. Exp Hematol 2002, 30(11):1283-1292.
38. Hock B.D., McKenzie J.L., Patton N.W., et al. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer 2006, 106(10):2148-2157.
39. Hattori K., Naguro I., Runchel C., et al. The roles of ASK family proteins in stress responses and diseases. Cell Commun Signal 2009, 7:9.
40. Yan W., Arai A., Aoki M., et al. ASK1 is activated by arsenic trioxide in leukemic cells through accumulation of reactive oxygen species and may play a negative role in induction of apoptosis. Biochem Biophys Res Commun 2007, 355(4):1038-1044.
41. Casely-Hayford M.A., Nicholas S.A., Sumbayev V.V. Azinomycin epoxide induces activation of apoptosis signal-regulating kinase 1 (ASK1) and caspase 3 in a HIF-1alpha-independent manner in human leukaemia myeloid macrophages. Eur J Pharmacol 2009, 602(2-3):262-267.
42. Ichijo H., Nishida E., Irie K., et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997, 275(5296):90-94.
43. D'Angelo S., Liebermann D., Hoffman B. The c-myc apoptotic response is not intrinsic to blocking terminal myeloid differentiation. J Cell Physiol 2008, 216(1):120-127.
44. Marcucci G., Radmacher M.D., Maharry K., et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358(18):1919-1928.
45. Debernardi S., Skoulakis S., Molloy G., et al. MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia 2007, 21(5):912-916.
46. Corey S.J., Minden M.D., Barber D.L., et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007, 7(2):118-129.
47. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(5):937-951.
48. Kopterides P., Halikias S., Tsavaris N. Visceral leishmaniasis masquerading as myelodysplasia. Am J Hematol 2003, 74(3):198-199.
49. Hasle H., Kerndrup G., Jacobsen B.B., et al. Chronic parvovirus infection mimicking myelodysplastic syndrome in a child with subclinical immunodeficiency. Am J Pediatr Hematol Oncol 1994, 16(4):329-333.
50. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355(14):1456-1465.
51. Lin Y.W., Slape C., Zhang Z., et al. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood 2005, 106(1):287-295.
52. Chung Y.J., Choi C.W., Slape C., et al. Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell. Proc Natl Acad Sci U S A 2008, 105(37):14088-14093.
53. Grisendi S., Bernardi R., Rossi M., et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005, 437(7055):147-153.
54. Buonamici S., Li D., Chi Y., et al. EVI1 induces myelodysplastic syndrome in mice. J Clin Invest 2004, 114(5):713-719.
55. Moody J.L., Xu L., Helgason C.D., et al. Anemia, thrombocytopenia, leukocytosis, extramedullary hematopoiesis, and impaired progenitor function in Pten+/-SHIP-/- mice: a novel model of myelodysplasia. Blood 2004, 103(12):4503-4510.
56. Minella A.C., Loeb K.R., Knecht A., et al. Cyclin E phosphorylation regulates cell proliferation in hematopoietic and epithelial lineages in vivo. Genes Dev 2008, 22(12):1677-1689.
57. Zhou L., Nguyen A.N., Sohal D., et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood 2008, 112(8):3434-3443.
58. Peng J., Kitchen S.M., West R.A., et al. Myeloproliferative defects following targeting of the Drf1 gene encoding the mammalian diaphanous related formin mDia1. Cancer Res 2007, 67(16):7565-7571.
59. Ebert B.L. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia 2009, 23(7):1252-1256.
60. Ebert B.L., Pretz J., Bosco J., et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008, 451(7176):335-339.
61. Lehmann S., O'Kelly J., Raynaud S., et al. Common deleted genes in the 5q-syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia 2007, 21(9):1931-1936.
62. Barlow J.L., Drynan L.F., Hewett D.R., et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nat Med 2010, 16:59-66.
63. Kerbauy D.M., Lesnikov V., Abbasi N., et al. NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood 2005, 106(12):3917-3925.
64. Fabre C., Carvalho G., Tasdemir E., et al. NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 2007, 26(28):4071-4083.
65. Pyatt D.W., Stillman W.S., Yang Y., et al. An essential role for NF-kappaB in human CD34(+) bone marrow cell survival. Blood 1999, 93(10):3302-3308.
66. Braun T., Carvalho G., Coquelle A., et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006, 107(3):1156-1165.
67. Rupec R.A., Jundt F., Rebholz B., et al. Stroma-mediated dysregulation of myelopoiesis in mice lacking I kappa B alpha. Immunity 2005, 22(4):479-491.
68. Maratheftis C.I., Andreakos E., Moutsopoulos H.M., et al. Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes. Clin Cancer Res 2007, 13(4):1154-1160.
69. Kerbauy D.B., Deeg H.J. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 2007, 35(11):1739-1746.
70. Hofmann W.K., de Vos S., Komor M., et al. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002, 100(10):3553-3560.
71. Sawanobori M., Yamaguchi S., Hasegawa M., et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 2003, 27(7):583-591.
72. Starczynowski D.T., Vercauteren S., Telenius A., et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 2008, 112(8):3412-3424.
73. Gondek L.P., Tiu R., O'Keefe C.L., et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008, 111(3):1534-1542.
74. Verhoef G.E., De Schouwer P., Ceuppens J.L., et al. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992, 6(12):1268-1272.
75. Koike M., Ishiyama T., Tomoyasu S., et al. Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia. Leuk Res 1995, 19(9):639-644.
76. Herold M., Schmalzl F., Zwierzina H. Increased serum interleukin 6 levels in patients with myelodysplastic syndromes. Leuk Res 1992, 16(6-7):585-588.
77. Hsu H.C., Lee Y.M., Tsai W.H., et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology 2002, 63(1):64-69.
78. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005, 23:1-21.
79. Hawley R.G., Fong A.Z., Burns B.F., et al. Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus. J Exp Med 1992, 176(4):1149-1163.
80. Corral L.G., Haslett P.A., Muller G.W., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999, 163(1):380-386.
81. Dunbar A.J., Gondek L.P., O'Keefe C.L., et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008, 68(24):10349-10357.
82. Arron J.R., Vologodskaia M., Wong B.R., et al. A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated Akt activation. J Biol Chem 2001, 276(32):30011-30017.
83. Kuno Y., Abe A., Emi N., et al. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). Blood 2001, 97(4):1050-1055.
84. Kanie T., Abe A., Matsuda T., et al. TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways. Leukemia 2004, 18(3):548-555.
85. Yamada T., Fujieda S., Yanagi S., et al. IL-1 induced chemokine production through the association of Syk with TNF receptor-associated factor-6 in nasal fibroblast lines. J Immunol 2001, 167(1):283-288.
86. Brakensiek K., Langer F., Schlegelberger B., et al. Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br J Haematol 2005, 130(2):209-217.
87. Johan M.F., Bowen D.T., Frew M.E., et al. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 2005, 129(1):60-65.
88. Croker B.A., Kiu H., Nicholson S.E. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 2008, 19(4):414-422.
89. Scott M.J., Liu S., Shapiro R.A., et al. Endotoxin uptake in mouse liver is blocked by endotoxin pretreatment through a suppressor of cytokine signaling-1-dependent mechanism. Hepatology 2009, 49(5):1695-1708.
90. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002, 99(11):4079-4086.
91. Noman A.S., Koide N., Hassan F., et al. Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulation of MyD88 expression. Innate Immun 2009, 15(1):33-41.
92. Fehniger T.A., Byrd J.C., Marcucci G., et al. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood 2009, 113(5):1002-1005.
93. List A., Kurtin S., Roe D.J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352(6):549-557.